Douglass Winthrop Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Douglass Winthrop Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,917	Closed	-$318K	–	245
2016 Q3	$318K	Sell	6,917 -283	-4%	-$14.8K	0.02%	189
2016 Q2	$362K	Hold	7,200	–	–	0.03%	177
2016 Q1	$385K	Hold	7,200	–	–	0.03%	167
2015 Q4	$473K	Hold	7,200	–	–	0.04%	167
2015 Q3	$407K	Hold	7,200	–	–	0.03%	175
2015 Q2	$449K	Hold	7,200	–	–	0.03%	178
2015 Q1	$449K	Sell	7,200 -1,548	-18%	-$90K	0.03%	178
2014 Q4	$503K	Hold	8,748	–	–	0.04%	131
2014 Q3	$470K	Buy	+8,748	New	+$463K	0.04%	132

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Douglass Winthrop Advisors's TEVA Position: Q4 2016 in Review

Douglass Winthrop Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 6,917 shares — an estimated $318K sold.

Douglass Winthrop Advisors first reported a position in TEVA in Q3 2014 and held it in 9 quarters. The position peaked at $503K in Q4 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Douglass Winthrop Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Douglass Winthrop Advisors sold 6,917 Teva Pharmaceuticals shares in Q4 2016, an estimated $318K.
Douglass Winthrop Advisors first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Douglass Winthrop Advisors's Teva Pharmaceuticals position peaked at $503K in Q4 2014.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Douglass Winthrop Advisors's 13F filing for Q4 2016, filed 31 Jan 2017.